Atossa Therapeutics Inc Stock Price, News & Analysis

Atossa Therapeutics (Nasdaq: ATOS) will host a webinar on August 25, 2022, featuring CEO Dr. Steven Quay and CFO Kyle Guse. The event, starting at 8 AM Pacific, will discuss new opportunities for AT-H201, an inhalation therapy aimed at treating lung injuries from cancer treatments. Attendees can participate in a Q&A session regarding the company's research programs and future plans. Registration for the complimentary event is available online.

Atossa Therapeutics (Nasdaq: ATOS) announced the re-appointment of Drs. Mak Jawadekar, Per Hall, and Carl Novina to its Scientific Advisory Board (SAB) alongside the addition of Dr. Paul Wabnitz. The re-appointments are expected to strengthen Atossa's product development in oncology and infectious diseases, particularly in breast cancer and COVID-19. Dr. Wabnitz brings extensive clinical development experience, having worked on numerous oncology trials. This move aims to leverage their expertise to enhance Atossa's clinical programs and navigate challenges in drug development.

Atossa Therapeutics (Nasdaq: ATOS) reported its Q2 2022 financial results, highlighting key developments in their oncology and COVID-19 projects. The company completed dosing for AT-H201 in a Phase 1/2a trial aimed at hospitalized COVID-19 patients. Subsequently, they are shifting focus towards developing AT-H201 for cancer patients with lung damage from treatment. Financially, Atossa recorded operating expenses of $6,595, a 6% decrease from Q2 2021, with R&D expenses at $3,433, down 10%. Cash reserves stood at approximately $125,647, with no sustainable revenue reported.

Atossa Therapeutics (Nasdaq: ATOS) has completed dosing in Part C of its Phase 1/2a clinical study for AT-H201, an inhalation therapy aimed at treating lung injury from cancer treatments. The study involved administering two FDA-approved drugs in healthy volunteers. Due to evolving COVID-19 treatment landscapes, Atossa is shifting focus from COVID-19 to patients with lung injuries from radiation therapy, affecting 30-60% of cancer patients. The company plans to pursue this new development path and announce next steps in Q4 2022.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced the appointment of Charles Butler as vice president of investor and public relations, effective June 2, 2022. With 25 years of experience in healthcare communications, Butler previously led communications at Exelixis, contributing to over $1B raised. His expertise is expected to enhance Atossa’s communications strategy as the company continues to develop innovative treatments for breast cancer and COVID-19. The management anticipates that Butler will play a crucial role in conveying Atossa's message of innovation within a competitive market.

On May 18, 2022, Atossa Therapeutics (Nasdaq: ATOS) announced that CFO Kyle Guse will present a corporate overview at the H.C. Wainwright Global Hybrid Investment Conference. The event takes place from May 23-26, 2022, at Fontainebleau Hotel in Miami Beach, FL, with Guse's presentation scheduled for May 24 at 12:30 PM ET. Attendees can request one-on-one meetings and register for both in-person and virtual participation.

Atossa focuses on developing innovative treatments for significant medical needs, particularly in oncology and infectious diseases.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) reported its Q1 2022 financial results, revealing no sustainable revenue and an operating loss of $4.7 million. Operating expenses rose 34% year-over-year to $4.7 million, primarily due to increased R&D expenses of $1.5 million and G&A expenses of $3.2 million, each reflecting heightened clinical trial activities. The company maintains cash reserves of approximately $131.6 million. Key advancements include a new U.S. patent for Endoxifen and the initiation of a Phase 2 study in premenopausal women with breast cancer, with an IND submission expected in Q2 2022.

Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company focusing on oncology and infectious diseases, will present at the Q2 Investor Summit Conference on May 3-4, 2022. Kyle Guse, CFO and General Counsel, will provide a corporate overview during the event. The presentation is scheduled for May 3, 2022, at 10:15 am ET. Investors can access the presentation through a webcast link and request one-on-one meetings.

Atossa Therapeutics, Inc. (Nasdaq: ATOS) has successfully completed participant enrollment for Part B of its Phase 1/2a clinical study of AT-H201 in Australia, focusing on inhalation therapy for COVID-19 patients and long-haulers. The study aims to investigate the efficacy of AT-H201 in improving lung function in both moderately to severely ill patients. While there’s a pressing need for additional therapies amid COVID-19 surges, the pathway to commercialization requires successful clinical outcomes and regulatory approvals. No assurances of success or approval are guaranteed.